Almost a year ago, China’s Shanghai Henlius Biotech achieved a major milestone for Chinese biosimilars by obtaining the first approval from the country’s National Medical Products Administration for its rituximab biosimilar, HLX01.
The biosimilar to Roche’s MabThera, for treating non-Hodgkin’s lymphoma, in February 2019 became the first biosimilar to be approved under...